Zenas BioPharma (ZBIO) Stock Price, News & Analysis

Company Overview

Zenas BioPharma, Inc. is a clinical-stage biotechnology company focused on the discovery and development of novel therapies in oncology and infectious diseases. The company’s proprietary platform integrates structure-guided design, computational modeling and high-throughput screening to address challenging protein-protein interactions. Zenas BioPharma is advancing multiple preclinical and clinical-stage candidates aimed at providing new treatment options where current modalities may be limited by efficacy or safety concerns.

Founded in 2021 and headquartered in Cambridge, Massachusetts, Zenas BioPharma was built to streamline the drug discovery process from target identification through to IND-enabling studies. Its integrated research infrastructure encompasses medicinal chemistry, in vitro and in vivo pharmacology, as well as manufacturing capabilities to support rapid progression of lead molecules into clinical development.

The company’s pipeline includes immuno-oncology candidates designed to modulate checkpoint pathways in solid tumors, alongside antiviral programs targeting broad-spectrum viral threats. Each program is engineered to combine high specificity with favorable pharmacokinetic properties, with key assets currently in IND-enabling stages and early clinical trials.

To advance its programs, Zenas BioPharma collaborates with academic institutions and contract research organizations, leveraging external expertise and resources. Serving global markets, the company is committed to addressing unmet medical needs and bringing differentiated therapies to patients worldwide.

Key Stats

• Today's Range: $20.31 to $22.18
• 50-Day Range: $9.79 to $21.84
• 52-Week Range: $5.83 to $26.25
• Volume: 339,620 shs
• Average Volume: 189,166 shs
• Market Capitalization: $924.31 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $36.67
• Consensus Rating: Buy

Zenas BioPharma Stock Analysis - MarketRank™

Zenas BioPharma scored higher than 21% of companies evaluated by MarketBeat, and ranked 880th out of 960 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Zenas BioPharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.

Upside Potential

Zenas BioPharma has a consensus price target of $36.67, representing about 67.0% upside from its current price of $21.95.

Amount of Analyst Coverage

Zenas BioPharma has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Zenas BioPharma is -6.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Zenas BioPharma is -6.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Zenas BioPharma has a P/B Ratio of 2.93. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

57.20% of the float of Zenas BioPharma has been sold short.

Short Interest Ratio / Days to Cover

Zenas BioPharma has a short interest ratio ("days to cover") of 29.5, which indicates bearish sentiment.

Change versus previous month

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Zenas BioPharma does not currently pay a dividend.

Dividend Growth

Zenas BioPharma does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

57.20% of the float of Zenas BioPharma has been sold short.

Short Interest Ratio / Days to Cover

Zenas BioPharma has a short interest ratio ("days to cover") of 29.5, which indicates bearish sentiment.

Change versus previous month

News and Social Media

• Score: 1.6 / 5
• News Sentiment: 0.89

News Sentiment

Zenas BioPharma has a news sentiment score of 0.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Zenas BioPharma this week, compared to 10 articles on an average week.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Zenas BioPharma insiders have not sold or bought any company stock.

Percentage Held by Insiders

16.50% of the stock of Zenas BioPharma is held by insiders. A high percentage of insider ownership can be a sign of company health.

ZBIO Stock Analysis - Frequently Asked Questions

How have ZBIO shares performed this year?

Zenas BioPharma's stock was trading at $7.90 on January 1st, 2025. Since then, ZBIO stock has increased by 177.8% and is now trading at $21.95.

How were Zenas BioPharma's earnings last quarter?

Zenas BioPharma, Inc. (NASDAQ:ZBIO) announced its earnings results on Tuesday, August, 12th. The company reported ($1.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.02) by $0.23.

When did Zenas BioPharma IPO?

Zenas BioPharma (ZBIO) raised $225 million in an initial public offering (IPO) on Friday, September 13th 2024. The company issued 13,235,294 shares at a price of $17.00 per share.

Who are Zenas BioPharma's major shareholders?

Top institutional shareholders of Zenas BioPharma include Federated Hermes Inc. (4.45%), Geode Capital Management LLC (0.89%), Schroder Investment Management Group (0.37%) and Rhumbline Advisers (0.05%).

How do I buy shares of Zenas BioPharma?

Shares of ZBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Zenas BioPharma own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Zenas BioPharma investors own include AST SpaceMobile (ASTS), Tempus AI (TEM), Trade Desk (TTD), Advanced Micro Devices (AMD), Biosig Technologies (BSGM), Ford Motor (F) and Genius Sports (GENI).

Company Calendar

• Last Earnings: 8/12/2025
• Today: 9/15/2025
• Next Earnings (Estimated): 11/11/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:ZBIO
• Previous Symbol: NASDAQ:ZBIO
• CIK: 1953926
• Web: N/A
• Phone: (857) 271-2954
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Zenas BioPharma: $36.67
• High Price Target: $45.00
• Low Price Target: $30.00
• Potential Upside/Downside: +67.0%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($3.55)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$156.99 million
• Net Margins: N/A
• Pretax Margin: -1,178.42%
• Return on Equity: -59.21%
• Return on Assets: -50.56%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.23
• Quick Ratio: 5.23

Sales & Book Value

• Annual Sales: $5 million
• Price / Sales: 184.86
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $7.48 per share
• Price / Book: 2.93

Miscellaneous

• Outstanding Shares: 42,110,000
• Free Float: 35,162,000
• Market Cap: $924.31 million
• Optionable: N/A
• Beta: N/A